Sino Biopharm's benmelstobart shows promise in lung cancer treatment

Sino Biopharmaceutical Limited (HKEX:1177) announced positive results from its Phase III CAMPASS study evaluating benmelstobart in combination with anlotinib as a first-line treatment for PD-L1 positive NSCLC. Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study demonstrated that the combination achieved its primary endpoint of progression-free survival (PFS). The median PFS was prolonged by more than 6 months in patients with TPS ≥50%, and the risk of disease progression or death was reduced by 40% compared to pembrolizumab. Overall, the combination therapy achieved a median PFS of 11.0 months, a 3.9-month improvement compared to the pembrolizumab arm's 7.1 months, with a 30% reduction in the risk of disease progression/death (HR=0.70). The confirmed objective response rate (ORR) was 57.3% and the disease control rate (DCR) was 85.9% for the benmelstobart combination, significantly higher than pembrolizumab's 39.5% and 79.1%, respectively.